NLRC4 and infection: Moreover, specific targeting of NLRP3 (and not of the major anti-microbial inflammasomes NLRC4 and NLRP1) may explain why MCC950 is less immunosuppressive than biologic compounds (e.g., Canakinumab, which may clinically increase the risk of serious infections (8, 17).